Tomonori Hirashima, Hidekazu Suzuki, Tomohiro Kanai, Hiroko Yoshida, Yoshitaka Tamura, Norio Okamoto, Toshio Tanaka
A previous study examined the potential of using interferon-γ (IFN-γ) release as a biomarker. Twenty-nine patients treated with immune checkpoint inhibitors were divided into three groups based on their level of IFN-γ release in the positive control after an enzyme-linked immunosorbent assay. The three groups showed clear differences in clinical outcomes. IGR may be a new dynamic biomarker to determine a patient’s immune status in the pre-treatment stage or any changes in their immune status during treatment for various diseases.
English 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi